MHC class I antigen presentation and implications for developing a new generation of therapeutic vaccines
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Major histocompatibility complex class I (MHC-I) presented peptide epitopes provide a ‘window’ into the changes occurring in a cell. Conventionally, these peptides are generated by proteolysis of endogenously synthesized proteins in the cytosol, loaded onto MHC-I molecules, and presented on the cell surface for surveillance by CD8+ T cells. MHC-I restricted processing and presentation alerts the immune system to any infectious or tumorigenic processes unfolding intracellularly and provides potential targets for a cytotoxic T cell response. Therefore, therapeutic vaccines based on MHC-I presented peptide epitopes could, theoretically, induce CD8+ T cell responses that have tangible clinical impacts on tumor eradication and patient survival. Three major methods have been used to identify MHC-I restricted epitopes for inclusion in peptide-based vaccines for cancer: genetic, motif prediction and, more recently, immunoproteomic analysis. Although the first two methods are capable of identifying T cell stimulatory epitopes, these have significant disadvantages and may not accurately represent epitopes presented by a tumor cell. In contrast, immunoproteomic methods can overcome these disadvantages and identify naturally processed and presented tumor associated epitopes that induce more clinically relevant tumor specific cytotoxic T cell responses. In this review, we discuss the importance of using the naturally presented MHC-I peptide repertoire in formulating peptide vaccines, the recent application of peptide-based vaccines in a variety of cancers, and highlight the pros and cons of the current state of peptide vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062 · cited 1×
“2010] and/or T cell induced exhaustion from continual antigen stimulation [Wherry, 2011; Baitsch et al.”
BackgroundHLA class I supertypes: a revised and updated classification
Sidney, J., Peters, B., Frahm, N., Brander, C., & Sette, A. (2008) · BMC Immunology · doi:10.1186/1471-2172-9-1 · Cited by 775
Sawada, Y., Yoshikawa, T., Nobuoka, D., Shirakawa, H., Kuronuma, T., Motomura, Y., Mizuno, S., Ishii, H., Nakachi, K., Konishi, M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3044 · Cited by 302 · cited 1×
“Sawada and colleagues demonstrated that vaccination of patients with hepatocellular carcinoma using a peptide derived from glypican-3 resulted in CD8+ T cell expansion with an improvement in overall survival in patients with robust GPC3 responses [Sawada et al. 2012].”
BackgroundSweeten PAMPs: Role of sugar complexed PAMPs in innate immunity and vaccine biology
Mahla, R. S. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00248 · Cited by 239 · cited 1×
“One active area of research in this regard is including TLR agonists in vaccine formulations, as these have been shown to heighten protective immune responses [Mahla et al. 2013].”
BackgroundSpeetjens, F. M., Kuppen, P. J. K., Welters, M. J. P., Essahsah, F., Voet van den Brink, A. M. E. G., Lantrua, M. G. K., Valentijn, A. R. P. M., Oostendorp, J., Fathers, L. M., Nijman, H. W., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2227 · Cited by 185
Cited by
PhysiCell: An open source physics-based cell simulator for 3-D multicellular systems
Ghaffarizadeh, A., Heiland, R., Friedman, S. H., Mumenthaler, S. M., & Macklin, P. (2018) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1005991 · Cited by 451
Vahidian, F., Duijf, P. H. G., Safarzadeh, E., Derakhshani, A., Baghbanzadeh, A., & Baradaran, B. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.03.004 · Cited by 75
Thioamide Analogues of MHC I Antigen Peptides
Gibadullin, R., Morris, R. K., Niu, J., Sidney, J., Sette, A., & Gellman, S. H. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c05300 · Cited by 17
Newkirk, S. E., Kelly, J. J., Hourn, N., Bhandari, S., Spencer, N., & Pires, M. M. (2026) · ACS Chemical Biology · doi:10.1021/acschembio.6c00291 · Cited by 2
Metadata
- Authors
- Comber, J. D., & Philip, R.
- Venue
- Therapeutic Advances in Vaccines
- Publisher
- SAGE Publications
- Published
- 2014-03-05
- Volume
- 2
- Issue
- 3
- Pages
- 77-89
- ISSN
- 2051-0136 (ISSN-L)
- 2051-0144
- OpenAlex
- W2169716006
- Cited by
- 140
- References
- 5
- FWCI
- 3.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: MHC class I antigen presentation and implications for developing a new generation of therapeutic vaccines. https://app.cochat.ai/papers/10.1177/2051013614525375
- The paper
- Comber, J. D., & Philip, R. (2014). MHC class I antigen presentation and implications for developing a new generation of therapeutic vaccines. Therapeutic Advances in Vaccines. https://doi.org/10.1177/2051013614525375
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.